Perspectives on "Chronic Lyme Disease"

American Journal of Medicine

Volumn 121, Issue 7, 2008, Pages 562-564

  Baker, Phillip J ^a  

^a American Lyme Disease Foundation   (United States)

Author keywords

Adverse effects of extended antibiotic therapy; Antibiotic therapy; Borrelia burgdorferi; Chronic Lyme disease; Extended antibiotic treatment; Lyme disease; Neuroprotective effects of antibiotics; Posttreatment Lyme disease syndrome

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CEPHALOSPORIN; DOXYCYCLINE; MACROLIDE; TETRACYCLINE;

ANTIBIOTIC THERAPY; BORRELIA BURGDORFERI; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFICACY; HUMAN; LYME DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; LYME DISEASE; TERMINOLOGY AS TOPIC;

EID: 45749090889     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.02.013     Document Type: Review

References (14)

1. Klempner M.S., Hu L.T., Evans J., et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 345 (2001) 85-92
2. Krupp L.B., Hyman L.G., Grimson, et al. Study and treatment of post Lyme disease (stop-LD): a randomized double-masked clinical trial. Neurology 60 (2003) 1923-1930
3. Patel R., Grogg K.L., Edwards W.D., et al. Death from inappropriate therapy for Lyme disease. Clin Infect Dis 31 (2000) 1107-1109
4. Shaffer E.A. Gall bladder sludge: what is its clinical significance?. Curr Gastroenterol Rep 3 (2001) 166-173
5. Owens Jr. R.C. Clostridium difficile-associated disease: an emerging threat to patient safety: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 26 (2006) 299-311
6. Moellering Jr. R.C., Graybill J.R., McGowan Jr. J.E., et al. Antimicrobial resistance prevention initiative-an update: proceedings of an expert panel. Am J Med 120 (2007) S4-S25
7. Sigal L.H. Misconceptions about Lyme disease: confusions hiding behind ill-chosen terminology. Ann Intern Med 136 (2002) 413-419
8. Domercq M., and Matute C. Neuroprotection by tetracyclines. Trends Pharmacol Sci 25 (2004) 609-612
9. Rothstein J.D., Patel S., Regan M.R., et al. β-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433 (2005) 73-77
10. Maier K., Merkler D., Gerber J., et al. Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation. Neurobiol Dis 25 (2007) 514-525
11. Weissenbacher S., Ring J., and Hofman H. Gabapentin for the symptomatic treatment of chronic neuropathic pain in patients with late-stage Lyme borreliosis: a pilot study. Dermatology 211 (2005) 123-127
12. Wormser G.P., Dattwyler R.J., Shapiro E.D., et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 43 (2006) 1089-1134
13. Halperin J.J., Shapiro E.D., Logigian E., et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review). Neurology 69 (2007) 91-102
14. Feder Jr. H.M., Johnson B.J.B., O'Connell S., et al. A critical appraisal of "chronic Lyme disease.". N Engl J Med 357 (2007) 1422-1430